Teva Pharmaceutical Industries Ltd., the troubled Israeli manufacturer of generic drugs, will be moving its US headquarters from Pennsylvania to New Jersey, lured by 10-year, $40 million tax incentive plan.
SUBSCRIBE
Biohealth Innovation
Founding Member of
